| Schedule of reportable segment information |
| | | | | | | | | | | | | | | | Three months ended June 30, | | Six months ended June 30 | | | | 2025 | | 2024 | | 2025 | | 2024 | | Revenue | | $ | 8,217 | | $ | 14,465 | | $ | 17,052 | | $ | 30,368 | | Less: | | | | | | | | | | | | | | Cost of revenue | | | 668 | | | 1,139 | | | 1,545 | | | 2,267 | | Research and development (1) | | | 1,230 | | | 1,417 | | | 2,536 | | | 2,530 | | Sales | | | 964 | | | 1,528 | | | 1,891 | | | 3,021 | | Sales operations | | | 741 | | | 778 | | | 1,526 | | | 1,563 | | General and administration | | | 5,121 | | | 2,926 | | | 9,995 | | | 5,773 | | Litigation contingency | | | — | | | — | | | 29,750 | | | — | | Depreciation and amortization | | | 109 | | | 170 | | | 211 | | | 346 | | Other segment expenses (2) | | | 1,437 | | | 1,157 | | | 2,754 | | | 2,542 | | Segment operating (loss) profit | | $ | (2,053) | | $ | 5,350 | | $ | (33,156) | | $ | 12,326 | | | | | | | | | | | | | | | | Interest income (expense), net | | | 76 | | | 712 | | | (21) | | | 1,531 | | Interest on 2030 Senior Notes | | | (1,220) | | | | | | (2,065) | | | — | | Impairment of investments | | | — | | | — | | | (1,000) | | | — | | Change in fair value of notes | | | — | | | 128 | | | — | | | 128 | | Change in fair value of digital assets | | | 83,761 | | | (5,055) | | | 41,932 | | | (5,055) | | Other corporate (expense) income (3) | | | (1) | | | 2 | | | 3 | | | 3 | | Income before taxes | | | 80,563 | | | 1,137 | | | 5,693 | | | 8,933 | | Income tax expense | | | 13,630 | | | 1,126 | | | 3,463 | | | 2,849 | | Net income | | $ | 66,933 | | $ | 11 | | $ | 2,230 | | $ | 6,084 | |
| 1. | Research and development expenses include clinical affairs and HITRUST. |
| 2. | Other segment expenses include marketing, customer education and business development. |
| 3. | Other corporate (expense) income represents unallocated (expense) income. |
|